p53 Review Article

You have free access to this content

TP53 and head and neck neoplasms†

  1. Hélène Blons1,
  2. Pierre Laurent-Puig1,2,*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10171

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 252–257, March 2003

Additional Information

How to Cite

Blons, H. and Laurent-Puig, P. (2003), TP53 and head and neck neoplasms. Hum. Mutat., 21: 252–257. doi: 10.1002/humu.10171

Author Information

  1. 1

    U490 INSERM Laboratoire de Toxicologie Moléculaire, Paris, France

  2. 2

    Service de chirurgie digestive générale et oncologique, Assistance Publique Hôpitaux de Paris, Hôpital Georges Pompidou 20, Paris, France

*U490 INSERM, Laboratoire de Toxicologie Moléculaire, 45 rue des Saints Pères 75006 Paris, France

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (116K)

REFERENCES

  • Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, Sidransky D. 2000. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 60:3155–3159.
  • Alsner J, Sorensen SB, Overgaard J. 2001. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 59:179–185.
  • Balaram P, Sridhar H, Rajkumar T, Vaccarella S, Herrero R, Nandakumar A, Ravichandran K, Ramdas K, Sankaranarayanan R, Gajalakshmi V, Munoz N, Franceschi S. 2002. Oral cancer in southern India: the influence of smoking, drinking, paan-chewing and oral hygiene. Int J Cancer 98:440–445.
    Direct Link:
  • Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S, Harabuchi Y. 2002. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer 94:1968–1980.
    Direct Link:
  • Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T. 1996. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1228–1233.
  • Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D. 1993. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477–4480.
  • Boyle JO, Mao L, Brennan JA, Koch WM, Eisele DW, Saunders JR, Sidransky D. 1994. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 168:429–432.
  • Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, Hanash SM, Carey TE, Wolf GT. 1997. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of veterans affairs laryngeal cancer cooperative study group. Arch Otolaryngol Head Neck Surg 123:605–609.
  • Brennan CT, Sessions DG, Spitznagel Jr, Harvey JE. 1991. Surgical pathology of cancer of the oral cavity and oropharynx. Laryngoscope 101:1175–1197.
    Direct Link:
  • Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D. 1995a. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332:712–717.
  • Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D. 1995b. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332:429–435.
  • Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. 2000. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18:1465–1473.
  • Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I. 2001. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 93:725–730.
    Direct Link:
  • Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. 1996. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56:2488–2492.
  • Casse C, Chuan Hu Y, Benoit N, Sidransky D, Ahrendt SA. 2002. The XRCC1 codon 399 polymorphism is associated with G to A transitions in p53 non-small cell lung cancer. Proc AACR 2002 abstract 2003. p 3210.
  • Chow V, Yuen AP, Lam KY, Ho WK, Wei WI. 2001. Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck 23:286–291.
    Direct Link:
  • Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. 1998. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221–2232.
  • Clayman GL, Frank DK, Bruso PA, Goepfert H. 1999. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5:1715–1722.
  • Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, Beaune P, Zucman J, Laurent-Puig P. 2000. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 60:707–711.
  • Davidson TM, Nahum AM, Astarita RW. 1981. Microscopic controlled excisions for epidermoid carcinoma of the head and neck. Otolaryngol Head Neck Surg 89:244–251.
  • Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B. 1999. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 84:573–579.
    Direct Link:
  • Georgiou A, Gomatos IP, Ferekidis E, Syrigos K, Bistola V, Giotakis J, Adamopoulos G, Androulakis G. 2001. Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. Eur J Surg Oncol 27:574–580.
  • Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720.
  • Gonzalez-Moles MA, Galindo P, Gutierrez-Fernandez J, Sanchez-Fernandez E, Rodriguez-Archilla A, Ruiz-Avila I, Bravo M. 2001. P53 protein expression in oral squamous cell carcinoma. survival analysis. Anticancer Res 21:2889–2894.
  • Hirvikoski P, Kumpulainen E, Virtaniemi J, Johansson R, Haapasalo H, Marin S, Halonen P, Helin H, Raitiola H, Pukander J, Kellokumpu-Lehtinen P, Kosma VM. 1997. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 15:3111–3120.
  • Homann N, Nees M, Conradt C, Dietz A, Weidauer H, Maier H, Bosch FX. 2001. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res 7:290–296.
  • Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, Chang JT, Cheng AJ. 2001. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 22:1497–1503.
  • Huang MF, Chang YC, Liao PS, Huang TH, Tsay CH, Chou MY. 1999. Loss of heterozygosity of p53 gene of oral cancer detected by exfoliative cytology. Oral Oncol 35:296–301.
  • Jeannon JP, Soames J, Lunec J, Awwad S, Ashton V, Wilson JA. 2000. Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. Clin Otolaryngol 25:23–27.
    Direct Link:
  • Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, Goepfert H, Luna MA, Batsakis JG, El-Naggar AK. 1998. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer 82:2159–2165.
    Direct Link:
  • Ko Y, Abel J, Harth V, Brode P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Thier R, Sachinidis A, Vetter H, Bolt HM, Herberhold C, Bruning T. 2001. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 61:4398–4404.
  • Kokoska MS, Piccirillo JF, el-Mofty SK, Emami B, Haughey BH, Schoinick SB. 1996. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 78:1693–1700.
    Direct Link:
  • Lavieille JP, Gazzeri S, Riva C, Reyt E, Brambilla C, Brambilla E. 1998. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck. Anticancer Res 18:4741–4749.
  • Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. 1994. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54:3662–3667.
  • Ma L, Ronai A, Riede UN, Kohler G. 1998. Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol 124:389–396.
  • Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J. 1998. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 78:1084–1090.
  • Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. 2001. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125–1131.
  • Muir C, Weiland L. 1995. Upper aerodigestive tract cancers. Cancer 75:147–153.
    Direct Link:
  • Nathan CA, Sanders K, Abreo FW, Nassar R, Glass J. 2000. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. Cancer Res 60:3599–3604.
  • Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D. 2001. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289–298.
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614.
    Direct Link:
  • Parkin DM, Laara E, Muir CS. 1988. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41:184–197.
    Direct Link:
  • Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. 2000. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst 92:69–73.
  • Sittel C, Eckel HE, Damm M, von Pritzbuer E, Kvasnicka HM. 2000. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope 110:1012–1017.
    Direct Link:
  • Soussi T, Beroud C. 2003. Significance of p53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat 21:192–200.
    Direct Link:
  • Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ. 2001. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7:1523–1532.
  • Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. 1999. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 30:1221–1225.
  • Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P. 2000. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385–394.
  • Thier R, Bruning T, Roos PH, Bolt HM. 2002. Cytochrome P450 1B1, a new keystone in gene-environment interactions related to human head and neck cancer? Arch Toxicol 76:249–256.
  • Tjebbes GW, Leppers vd Straat FG, Tilanus MG, Hordijk GJ, Slootweg PJ. 1999. p53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: p53 mutations in primary tumor and matched lymph node metastases. Oral Oncol 35:384–389.
  • Toyooka S, Tsuda T, Gazdar AF. 2003. The TP53 gene, tobacco exposure and lung cancer. Hum Mutat 21:229–239.
    Direct Link:
  • Tuyns AJ, Esteve J, Raymond L, Berrino F, Benhamou E, Blanchet F, Boffetta P, Crosignani P, del Moral A, Lehmann W, et al. 1988. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer 41:483–491.
    Direct Link:
  • van Houten VM, Tabor MP, van den Brekel MW, Denkers F, Wishaupt RG, Kummer JA, Snow GB, Brakenhoff RH. 2000. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 6:3803–3816.
  • Warnakulasuriya S. 2000. Lack of molecular markers to predict malignant potential of oral precancer. J Pathol 190:407–409.
    Direct Link:
  • Wong RH, Du CL, Wang JD, Chan CC, Luo JC, Cheng TJ. 2002. XRCC1 and CYP2E1 polymorphisms as susceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomer-exposed polyvinyl chloride workers. Cancer Epidemiol Biomarkers Prev 11:475–482.
Get PDF (116K)